Moleculin Biotech Inc (MBRX) Stock Analysis

Moleculin Biotech Inc (MBRX) is a publicly traded company in the HEALTHCARE sector. It trades at $2.64, carries a market capitalization of $14.09M. This page summarizes the public market data, fundamentals, and frequently asked questions for MBRX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Moleculin Biotech Inc currently has a Bullish sentiment score of 0.44.

About Moleculin Biotech Inc

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company located in Houston, Texas, specializing in innovative therapies for cancer and viral infections. It is leveraging proprietary technology to advance a diverse pipeline of drug candidates designed to tackle highly resistant tumors and address significant unmet needs in oncology. With its commitment to scientific rigor and breakthrough treatments, Moleculin Biotech is well-positioned to make a substantial impact on the future of ...

GNG Research Analysis

GNG Research scores Moleculin Biotech Inc (MBRX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for MBRX.

Frequently Asked Questions

Does MBRX pay dividends?

Moleculin Biotech Inc (MBRX) does not currently pay a regular dividend.

What is MBRX's market cap?

Moleculin Biotech Inc (MBRX) has a market capitalization of $14.09M with a current stock price of $2.64.